Aditxt announces termination of arrangement agreement with Appili Therapeutics

Aditxt (ADTX) announced that it has determined it is in the best interest of the company and its stockholders to terminate the previously announced arrangement agreement with Appili Therapeutics (APLIF). The arrangement agreement, originally announced in April 2024, had been amended several times to extend key milestones and accommodate changing circumstances. Despite these efforts, Aditxt has concluded that it is no longer strategically aligned to move forward under the terms of the agreement. Management intends to formally notify Appili of the termination, effective May 31. Further details will be provided as appropriate.